Flindr Therapeutics
Joëlle Vos is an experienced professional in operations and analytics, currently serving as the Head of Operations and Analytics at Flindr Therapeutics since January 2025, focusing on precision oncology medicine development. Prior to this role, Joëlle was a Principal Consultant at Hezelburcht Grant & Funding Consultancy from February 2017 to December 2024, where support was provided for clients' grant-related ambitions. Joëlle's earlier positions include Senior Consultant and Consultant roles, along with research experience at Karolinska Institutet, where contributions were made to health innovations and open industry-university collaborations. Education includes multiple degrees from Radboud University, encompassing a Master’s in Science, Management, and Innovation, as well as a Master’s and Bachelor’s in Medical Biology.
This person is not in any teams
This person is not in any offices
Flindr Therapeutics
Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Innovatiefonds Noord Holland, and BOM. Flindr has entered into a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology).